Latest Mrna Vaccines News

Moderna returned to quarterly GAAP profit, raised its 2026 revenue growth outlook and reported positive Phase 3 melanoma data. The stronger quarter was supported by international COVID vaccine sales, while cash generation and pipeline execution remain important tests.

IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.

CSL Limited has released its half-year results showing a slight revenue decline amid ongoing transformation efforts, while maintaining its full-year guidance and expanding its share buyback program.

CSL Limited reported a 7% decline in underlying NPATA to US$1.9 billion for the half-year, weighed down by restructuring costs and impairments, yet maintains full-year guidance and expands its share buy-back program.

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.